In a report released today, Andrew Paine from CLSA maintained a Buy rating on CSL, with a price target of A$275.00. The company’s shares closed last Friday at $130.18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Paine is a 3-star analyst with an average return of 3.3% and a 51.96% success rate. Paine covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, CSL, and Telix Pharmaceuticals.
In addition to CLSA, CSL also received a Buy from UBS’s Marcus Curley in a report issued on October 8. However, on October 3, Canaccord Genuity maintained a Hold rating on CSL (Other OTC: CMXHF).
The company has a one-year high of $207.00 and a one-year low of $124.73. Currently, CSL has an average volume of 874.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CMXHF in relation to earlier this year.
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
